Dr. Benji K. Mathews praises mentors for his SHM roles

Benji K. Mathews, MD, SFHM, CLHM, is chief of hospital medicine at Regions Hospital in Saint Paul, Minn., and director of point-of-care ultrasound (POCUS) for hospital medicine at HealthPartners. He is also the course director for the Society of Hospital Medicine’s 2020 (HM20) annual conference, to be held April 15-18 in San Diego.

Dr. Mathews, an associate professor of medicine at the University of Minnesota, Minneapolis, is recognized by fellow hospitalists as a pioneer in the use of bedside ultrasound. In fact, his Certificate of Leadership in Hospital Medicine (CLHM) was completed with a focus on ultrasound in hospital medicine, and he is a Fellow in Diagnostic Safety through the Society to Improve Diagnosis in Medicine. “While a resident, I took an interest in the field of improving diagnosis and combined it with

Continued on page 8
By Matt Pesyna

Swati Mehta, MD, recently was honored as the lone hospitalist on the National Executive Physician Council for Beryl Institute (Nashville, Tenn.). Only 24 total hospitalists were selected to the council. Dr. Mehta also was named the 2019 Distinguished Physician Award winner at Vituity (Emeryville, Calif.), where she is the executive director of quality and performance.

A nocturnist at Sequoia Hospital (Redwood City, Calif.), Dr. Mehta is a member of the Society of Hospital Medicine’s Patient Experience interest group.

Shannon Phillips, MD, SFHM, has been named to the National Quality Forum’s Board of Directors for 2020. The chief patient experience officer at Intermountain Healthcare (Salt Lake City), she also is a recent member of the Performance Measurement and Reporting Committee.

Dr. Phillips, whose focus at Intermountain is on catalyzing quality, safety, and experience of care, was named a 2018 Becker’s Hospital Review Hospital and Health System CIO to Know. Previously, she worked at the Cleveland Clinic, where she was its first patient safety officer and an associate chief quality officer.

Vineet Arora, MD, MHM, has been elected as a new member of the National Academy of Medicine, which honors pioneering scientific and professional achievements within the field.

An academic hospitalist at the University of Chicago, Dr. Arora specializes in improving the learning environment for her medical trainees, as well as maintaining a high level of quality, safety, and care for patients. She also is considered an expert in using social media and other new technology to enhance medical education.

The National Academy of Medicine stated that Dr. Arora’s honor was “for pioneering work to optimize resident fatigue and patient safety during long shifts.”

Edmundo Robinson, MD, has been named senior vice president and chief digital innovation officer at Moffitt Cancer Center (Tampa). The chief digital innovation officer position is a newly created position that the veteran physician has assumed. Dr. Robinson has 16 years’ experience in clinical and technological work.

In this new position, Dr. Robinson, a practicing academic hospitalist, will head Moffitt’s digital innovation while looking to create and test new services, programs, partnerships, and technologies. Dr. Robinson comes to Moffitt after serving as chief transformation officer and senior vice president at ChristianaCare (Wilmington, Del.). A teacher at Sidney Kimmel Medical College, Philadelphia, Dr. Robinson was the founding medical director of ChristianaCare Hospitalist Partners.

Relias Healthcare (Tupelo, Miss.) has begun providing hospitalist and emergency medicine services for North Mississippi Health Services’ Gilmore-Amory Trauma Center. Relias, a multistate company that has partnered with more than 150 providers, now has a role at four different North Mississippi Health Services facilities.

Mednax (Sunrise, Fla.) has added Arcenio Chacon and Associated Pediatricians of Homestead (Fla.), a pediatric critical care and hospital practice, as an affiliate.

Chacon and Associated Pediatricians are based out of Miami and have served Baptist Health South Florida for more than 25 years. Established in 1979, Mednax is a health solutions company that provides subspecialty service in all 50 states.
Designing an effective onboarding program

By Farzan Irani, MD, MBA, MRCP, SFHM, FACP, CHCQM

As I gear up to welcome and onboard new hires to our hospitalist group, I could not help but reflect on my first day as a hospitalist. Fresh out of residency, my orientation was a day and a half long.

The medical director gave me a brief overview of the program. The program administrator handed me a thick folder of policies followed by a quick tour of the hospital and an afternoon training for the computerized order entry system (that was a time before EHRs). The next morning, I was given my full panel of patients, my new lab coat, and sent off into the battlefield.

I can vividly remember feeling anxious, a bit confused, and quite overwhelmed as I went through my day. The days turned into a week and the next. I kept wondering if I was doing everything right. It took me a month to feel a little more comfortable. It all turned out fine. Since nobody told me otherwise, I assumed it did.

Quite a bit has changed since then in hospital medicine. Hospital medicine groups, nowadays, have to tackle the changing landscape of payment reform, take on responsibility for an increasing range of hospital quality metrics, and juggle the next. I kept wondering if I was doing everything right. It took me a month to feel a little more comfortable. It all turned out fine. Since nobody told me otherwise, I assumed it did.

Quite a bit has changed since then in hospital medicine. Hospital medicine groups, nowadays, have to tackle the changing landscape of payment reform, take on responsibility for an increasing range of hospital quality metrics, and juggle the next. I kept wondering if I was doing everything right. It took me a month to feel a little more comfortable. It all turned out fine. Since nobody told me otherwise, I assumed it did.

The medical director gave me a brief overview of the program. The program administrator handed me a thick folder of policies followed by a quick tour of the hospital and an afternoon training for the computerized order entry system (that was a time before EHRs). The next morning, I was given my full panel of patients, my new lab coat, and sent off into the battlefield.

I can vividly remember feeling anxious, a bit confused, and quite overwhelmed as I went through my day. The days turned into a week and the next. I kept wondering if I was doing everything right. It took me a month to feel a little more comfortable. It all turned out fine. Since nobody told me otherwise, I assumed it did.

Quite a bit has changed since then in hospital medicine. The vast majority of physicians and advanced providers hired to a hospital medicine group have come immediately from training. Transition into the autonomous role of an attending, or a semi-autonomous role for advanced providers, with a larger patient panel can be quite unnerving and stressful. It can be disorientating even for experienced providers transitioning into a new health system. But it does not have to be quite so stressful.

The most common aspect of onboarding is providing new hires with information on the group’s policies and procedures: what to do and how to do it. Equality is essential is giving them the tools and contacts that will help them understand and navigate their first few months.

Information on how to contact consultants, sign on and off shifts, and so on can be easily conveyed through documents. However, having peers and the critical administrative staff communicate other aspects such as a detailed tour of the hospital, scheduling, and vacation policies is far more effective. It provides an excellent opportunity to introduce new hires to the key personnel in the group and vice versa as new hires get familiar with the unofficial workplace language.

Breaking down all this information into meaningful, absorbable boluses, spread over time, is key to avoiding information overload. Allowing new hires to assimilate and adapt to the group norms requires follow-up and reinforcement. Group leaders should plan to meet with them at predetermined intervals, such as at 30, 60, 90 days, to engage them in conversations about the group’s values, performance measurements, rewards, and the opportunities for growth that exist within the group and institution.

1. The organizational or administrative aspect: The majority of physicians and advanced providers hired to a hospital medicine group have come immediately from training. Transition into the autonomous role of an attending, or a semi-autonomous role for advanced providers, with a larger patient panel can be quite unnerving and stressful. It can be disorientating even for experienced providers transitioning into a new health system. But it does not have to be quite so stressful.

The most common aspect of onboarding is providing new hires with information on the group’s policies and procedures: what to do and how to do it. Equality is essential is giving them the tools and contacts that will help them understand and navigate their first few months.

Information on how to contact consultants, sign on and off shifts, and so on can be easily conveyed through documents. However, having peers and the critical administrative staff communicate other aspects such as a detailed tour of the hospital, scheduling, and vacation policies is far more effective. It provides an excellent opportunity to introduce new hires to the key personnel in the group and vice versa as new hires get familiar with the unofficial workplace language.

Breaking down all this information into meaningful, absorbable boluses, spread over time, is key to avoiding information overload. Allowing new hires to assimilate and adapt to the group norms requires follow-up and reinforcement. Group leaders should plan to meet with them at predetermined intervals, such as at 30, 60, 90 days, to engage them in conversations about the group’s values, performance measurements, rewards, and the opportunities for growth that exist within the group and institution.

2. The technical or the clinical aspect: The majority of physicians and advanced providers hired to a hospital medicine group have come immediately from training. Transition into the autonomous role of an attending, or a semi-autonomous role for advanced providers, with a larger patient panel can be quite unnerving and stressful. It can be disorientating even for experienced providers transitioning into a new health system. But it does not have to be quite so stressful.

The most common aspect of onboarding is providing new hires with information on the group’s policies and procedures: what to do and how to do it. Equality is essential is giving them the tools and contacts that will help them understand and navigate their first few months.

Information on how to contact consultants, sign on and off shifts, and so on can be easily conveyed through documents. However, having peers and the critical administrative staff communicate other aspects such as a detailed tour of the hospital, scheduling, and vacation policies is far more effective. It provides an excellent opportunity to introduce new hires to the key personnel in the group and vice versa as new hires get familiar with the unofficial workplace language.

Breaking down all this information into meaningful, absorbable boluses, spread over time, is key to avoiding information overload. Allowing new hires to assimilate and adapt to the group norms requires follow-up and reinforcement. Group leaders should plan to meet with them at predetermined intervals, such as at 30, 60, 90 days, to engage them in conversations about the group’s values, performance measurements, rewards, and the opportunities for growth that exist within the group and institution.

3. The social aspect – enculturation and networking: This is probably the most important of the three elements. It is quite common for new hires to feel like a stranger in a new land. A well-designed onboarding program provides new hires the space to forge relationships with each other and existing members of the hospital medicine team.

When done well, this helps transform a group into a community. It also lays the groundwork to avoid stress and loneliness, some of the culprits that lead to physician burnout. It is through these interpersonal connections that new hires adapt to a hospital medicine group’s prevailing culture.

The personnel

Effective onboarding should be more than mere orientation. Group leaders should make an active attempt at understanding the core values and needs of the group. A good onboarding process assists new hires to internalize and accept the norms of the group. This process is not just a result of what comes from top management but also what they see and hear from the rank and file providers in the group. Hence it is critical to have the right people who understand the organization effectively.
Two decades of leadership

In recognition of Dr. Larry Wellikson’s contributions to SHM

By Brian Harte, MD, MHM

It’s already been a few years since I exited the Society of Hospital Medicine’s Board of Directors (2 years, or maybe 3 – I’ve already lost count), and sitting in my proverbial rocking chair in the Old Hospitalists’ Home, I heard, as many of you did, that Larry Wellikson, MD, MHM, the first and only chief executive officer in the Society’s history, is stepping down soon.

With all the idle time that I find myself with these days, I have had the opportunity to ruminate on what Larry has brought to SHM in his 2 decades of leadership. And among the many answers, two stand out for me.

The first is Larry’s deep appreciation of the value of relationships that he has developed and nurtured, an attribute which he has imprinted on many of us who have worked with him over the years. Although Larry speaks of the camaraderie of the first years of SHM and the bonds that he, Dr. Bob Wachter, Dr. Win Whitcomb, and Dr. John Nelson established, he also has kept in touch with a vast network of hospitalists over the last 20-plus years.

Go to lunch with Larry, and be amazed at how much he knows about the goings-on of many of our colleagues. The fondness that Larry has for the people in his life is without parallel. These aren’t just professional colleagues who have impacted him in some way – for Larry, every one of these is a true lifetime friendship, and he continues to establish new ones every year. He makes each of his friends feel truly special to him.

The second is the critical value of and need for change and disruption. The specialty of hospital medicine was, from its beginning, disruptive, and from his career as a physician executive, Larry understood and has brought to SHM an understanding of the necessity of disruption to encourage growth and fresh thinking.

“The specialty of hospital medicine was, from its beginning, disruptive, and from his career as a physician executive, Larry understood and has brought to SHM an understanding of the necessity of disruption to encourage growth and fresh thinking.”

It is equally essential that necessary time and resources are devoted to building a program that meets the needs of the group. The practice management committee at SHM interviewed five different programs across a spectrum of settings. All of them had a designated onboarding program leader with a planning committee that included the administrative staff and senior frontline hospitalists.

The costs

According to one estimate, the cost of physician turnover is $400,000–$600,000 per provider.1 Given such staggering costs, it is not difficult to justify the financial resources required to structure an effective onboarding program. Activities such as a detailed facility tour, a welcome breakfast, and a peer buddy system cost virtually nothing. They go a long way in building comradery, make new hires feel like they are part of a team, and reduce burnout and turnover.

Costs of an onboarding program are typically related to wages during shadowing and clinical ramp-up. However, all the programs we interviewed acknowledged that the costs associated with onboarding, in the broader context, were small and necessary.

The bottom line

An effective onboarding program that is well planned, well structured, and well executed is inherently valuable. It sends a positive signal to new hires, reassuring them that they made a great decision by joining the group. It also reminds the existing providers why they want to be a part of the group and its culture.

It is not about what is said or done during the onboarding process or how long it lasts. It need not be overly complicated. It is how the process makes everyone feel about the group. At the end of the day, like in all aspects of life, that is what ultimately matters.

The SHM Practice Management Committee has created a document that outlines the guiding principles for effective onboarding with attached case studies. Visit the SHM website for more information: https://www.hospitalmedicine.org.

References


By Dr. Brian Harte

Dr. Harte is a past president of SHM, and president of Cleveland Clinic Akron (Ohio) General and the Southern Region. He formerly served as president of Cleveland Clinic Hillcrest Hospital and Cleveland Clinic South Pointe Hospital.
ENVISION PHYSICIAN SERVICES PROVIDES...

EXCELLENT OPPORTUNITIES
AND A GREAT CAREER PATH TO LEADERSHIP

DOLLY ABRAHAM, MD, MBA, SFHM
HOSPITAL MEDICINE

Featured Hospital Medicine Leadership Positions

**Aventura Hospital and Medical Center**
Miami, FL

**Portsmouth Regional Hospital**
Portsmouth, NH

**The Queen’s Medical Center**
Honolulu, HI

**Santa Rosa Memorial Hospital**
Santa Rosa, CA

**RWJ University Hospital**
New Brunswick, NJ

VISIT US AT HM20, Booth #913

855.668.7996
EVPS.com/TheHospitalist2020
The hospitalized post-bariatric surgery patient

What every hospitalist should know

By Jennifer C. Kerns, MD, MSHS

With the prevalence of obesity worldwide topping 650 million people and nearly 40% of U.S. adults having obesity, bariatric surgery is increasingly used to treat this disease and its associated comorbidities.

The American Society for Bariatric Surgery estimates that 228,000 bariatric procedures were performed on Americans in 2017, up from 158,000 in 2011.1 Despite lowering the risks of diabetes, stroke, myocardial infarction, cancer, and all-cause mortality2 bariatric surgery is associated with increased health care use. Neovius et al. found that people who underwent bariatric surgery used 54 mean cumulative hospital days in the 20 years following their procedures, compared with just 40 inpatient days used by controls.3 Although hospitalists are caring for increasing numbers of patients who have undergone bariatric surgery, many of us may not be aware of some of the things that can lead to hospitalization or otherwise affect inpatient medical care. Here are a few points to keep in mind the next time you care for an inpatient with prior bariatric surgery.

Pharmacokinetics change after surgery

Gastrointestinal anatomy necessarily changes after bariatric surgery and can affect the oral absorption of drugs. Because gastric motility may be impaired and the pH in the stomach is increased after bariatric surgery, the disintegration and dissolution of immediate-release solid pills or caps may be compromised. It is therefore prudent to crush solid forms or switch to liquid or chewable formulations of the immediate-release drugs for the first few weeks to months after surgery. Enteric-coated or long-acting drug formulations should not be crushed and should generally be avoided in patients who have undergone bypass procedures such as Roux-en-Y gastric bypass (RYGB) or biliopancreatic diversion with duodenal switch (BPD/DS), as they can demonstrate either enhanced or diminished absorption (depending on the drug).

Reduced intestinal transit times and changes in intestinal pH can alter the absorption of certain drugs as well, and the expression of some drug transporter proteins and enzymes such as the CYP3A4 variant of cytochrome P450—which is estimated to metabolize up to half of currently available drugs—varies between the upper and the lower small intestine, potentially leading to increased bioavailability of medications metabolized by this enzyme in patients who have undergone bypass surgeries.

Interestingly, longer-term studies have reexamined drug absorption in patients 2-4 years after RYGB and found that initially increased drug plasma levels often return to preoperative levels or even lower over time, likely because of adaptive changes in the GI tract. Because research on the pharmacokinetics of individual drugs after bariatric surgery is lacking, the hospitalist should be aware that the bioavailability of oral drugs is often altered and should monitor patients for the desired therapeutic effect as well as potential toxicities for any drug administered to post–bariatric surgery patients.

Finally, note that nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and corticosteroids should be avoided after bariatric surgery unless the benefit clearly outweighs the risk, as they increase the risk of ulcers even in patients without underlying surgical disruptions to the gastric mucosa.

Micronutrient deficiencies are common and can occur at any time

While many clinicians recognize that vitamin deficiencies can occur after weight loss surgeries which bypass the duodenum, such as the RYGB or the BPD/DS, it is important to note that vitamin and mineral deficiencies occur commonly even in patients with intact intestinal absorption such as those who underwent sleeve gastrectomy (SG) and even despite regained weight due to greater volumes of food and (micronutrient) intake over time.

The most common vitamin deficiencies include iron, vitamin B12, thiamine (vitamin B1), and vitamin D, but deficiencies in other vitamins and minerals may be as well. Anemia, bone fractures, heart failure, and encephalopathy can all be related to postoperative vitamin deficiencies. Most bariatric surgery patients should have micronutrient levels monitored on a yearly basis and should be taking at least a multivitamin with minerals (including zinc, copper, selenium and iron), a form of vitamin B12, and vitamin D with calcium supplementation. Additional supplements may be appropriate depending on the type of surgery the patient had or whether a deficiency is found.

The differential diagnosis for abdominal pain after bariatric surgery is unique

While the usual suspects such as diverticulitis or gastritis should be considered in post–bariatric surgery patients just as in others, a few specific complications can arise after weight loss surgery.

Marginal ulcerations (ulcers at the surgical anastomotic sites) have been reported in up to a third of patients complaining of abdominal pain or dysphagia after RYGB, with tobacco, alcohol, or NSAID use conferring even greater risk. Easily upper endoscopy may be warranted in symptomatic patients.

Small-bowel obstruction (SBO) may occur because of surgical adhesions as in other patients, but catastrophic internal hernias with associated volvulus can occur because of specific anatomical defects that are created by the RYGB and BPD/DS procedures. CT imaging is insensitive and can miss up to 30% of these cases, and nasogastric tubes placed blindly for decompression of an SBO can lead to perforation of the end of the alimentary limb at the gastric pouch outlet, so post-RYGB or BPD/DS patients presenting with signs of SBO should have an early surgical consult for expeditious surgical management rather than a trial of conservative medical management.

Cholelithiasis is a very common postoperative complication, occurring in about 25% of SG patients and 32% of RYGB patients in the first year following surgery. The risk of gallstone formation can be significantly reduced with the postoperative use of ursodeoxycholic acid.

Onset of abdominal cramping, nausea and diarrhea (sometimes accompanied by yasomotor symptoms) within 15-60 minutes of eating may be due to early dumping syndrome. Rapid delivery of food from the gastric pouch into the small intestine causes the release of gut peptides and an osmotic fluid shift into the intestinal lumen that can trigger these symptoms even in patients with a preserved pyloric sphincter, such as those who underwent SG. Simply eliminating sugars

March 2020 6 The Hospitalist

Dr. Kerns is a hospitalist and codirector of bariatric surgery at the Washington DC VA Medical Center.
and simple carbohydrates from the diet usually resolves the problem, and eliminating lactose can often be helpful as well.

**Postprandial hyperinsulinemic hypoglycemia ("late dumping syndrome")** can develop years after surgery

Vasomotor symptoms such as flushing/sweating, shaking, tachycardia/palpitations, lightheadedness, or difficulty concentrating occurring 1-3 hours after a meal should prompt blood glucose testing, as delayed hypoglycemia can occur after a large insulin surge.

Most commonly seen after RYGB, late dumping syndrome, like early dumping syndrome, can often be managed by eliminating sugars and simple carbohydrates from the diet. The onset of late dumping syndrome has been reported as late as 8 years after surgery, so the etiology of symptoms can be elusive. If the diagnosis is unclear, an oral glucose tolerance test may be helpful.

**Alcohol use disorder is more prevalent after weight loss surgery**

Changes to the gastrointestinal anatomy allow for more rapid absorption of ethanol into the bloodstream, making the drug more potent in postop patients. Simultaneously, many patients who undergo bariatric surgery have a history of using food to buffer negative emotions. Abruptly depriving them of that comfort in the context of the increased potency of alcohol could potentially leave bariatric surgery patients vulnerable to the development of alcohol use disorder, even when they did not misuse alcohol preoperatively.

Of note, alcohol misuse becomes more prevalent after the first postoperative year. Screening for alcohol misuse on admission to the hospital is wise in all cases, but perhaps even more so in the post-bariatric surgery patient. If a patient does report excessive alcohol use, keep possible thiamine deficiency in mind.

**The risk of suicide and self-harm increases after bariatric surgery**

While all-cause mortality rates decrease after bariatric surgery compared with matched controls, the risk of suicide and nonfatal self-harm increases. About half of bariatric surgery patients with nonfatal events have substance misuse. Notably, several studies have found reduced plasma levels of SSRIs in patients after RYGB, so pharmacotherapy for mood disorders could be less effective after bariatric surgery as well. The hospitalist could positively impact patients by screening for both substance misuse and depression and by having a low threshold for referral to a mental health professional.

As we see ever-increasing numbers of inpatients who have a history of bariatric surgery, being aware of these common and important complications can help today’s hospitalist provide the best care possible.

**References**

the 21st-century innovative tool of bedside ultrasound,’ he said. ‘Now, I continue to teach clinicians, educators, and learners.’

In addition to his interest in POCUS and medical education, Dr. Mathews also has a passion for global health, rooted in a commitment to reducing health care disparities both locally and globally. He has worked with medical missions, nongovernmental organizations, and orphanages in Nepal, India, Bolivia, Honduras, and Costa Rica. This led him to complete the global health course at the University of Minnesota.

Dr. Mathews spent a few minutes with The Hospitalist to discuss his background and his new role of course director of the HM20 annual conference.

Can you describe your journey to becoming a hospitalist?

I’ve been a hospitalist for most of the last decade. I was fortunate to be a part of a great residency program at the University of Minnesota Medical School, which started a hospital medicine pathway that had several nationally recognized hospital medicine leaders as mentors. I was lucky to work with several of them through the HealthPartners organization in Saint Paul, and that developed in me a further desire to practice hospital medicine. The group and mentors provided opportunities to develop further niches in my practice, like bedside ultrasound.

How did you first get involved with SHM?

I entered SHM through the influence of mentors at HealthPartners, especially Burke Kealey, MD, SFHM, senior medical director for hospital specialties at HealthPartners Medical Group in Bloomington, Minn., and a past president of the Society, who encouraged me to participate in SHM committees. I eventually applied for the Annual Conference Committee, and somehow was accepted. At that time, I was a community hospitalist among a lot of academic hospitalists. I thought that my voice could probably diversify the conversation, and bring the perspective of an early-career hospitalist to the discussion around educational offerings at the Annual Conference. I benefited from good mentorship on that committee, and with that experience I started getting involved with our local chapter in Minnesota. That was very important. I became our local chapter president and was able to combine my efforts with SHM nationally with our regional initiatives.

You have a particular interest in point-of-care ultrasound for hospitalists. How did that make its way into your involvement with SHM?

Point-of-care ultrasound and diagnostic error work really took off when I was a resident. My interest in that funneled naturally into the base curriculum of the Annual Conference, where once a year I could come together with 18 of my best hospitalist friends from across the nation to discuss curriculum. We talk about what content is applicable for frontline clinicians, what is right for early learners, and what innovations are coming in the future. Toward that last point, I was always involved as a judge or volunteer for the Research, Innovations, and Clinical Vignettes – or RIV – competition at the Annual Conference. That’s the scientific abstract and poster competition at the conference. My interest grew to a point at which I decided to apply for one of the leadership roles in the RIV. I had the opportunity to serve as an Innovations Lead at RIV one year, and then chaired the overall RIV competition. Those opportunities helped me better understand the cutting-edge research that hospitalists should be aware of and which researchers and clinicians we should be in conversation with.

All these roles together have led me to my service as HM20 course director. I see myself as a lucky guy who has benefited from great mentorship, and I want to take advantage of my opportunities to serve.

We’ve been told that your elementary school-age children have learned to use ultrasound! Well, they’ve learned how to use handheld ultrasound devices on each other. They’re able to find their siblings’ kidneys and hearts. I often show an image of this to encourage hospitalists that, if children can pick it up, highly educated providers can do the same and more.

To register for the Society of Hospital Medicine’s 2020 Annual Conference, please visit the HM20 Registration page at https://shmanualconference.org/register.

HM20: Innovative and cutting edge

Come for the education, stay for the movement. Hospital Medicine 2020 (HM20), held April 15-18 in San Diego, will provide hospital medicine professionals with a unique blend of education and networking opportunities, including several new features:

• A live Simulation Center, featuring procedures and ultrasound (preregistration required)
• The Education Wall, where you can watch sessions live and earn CME
• HM Central, your one stop for all things HM20
• SURVIVE! The POCUS Apocalypse Adventure, an interactive workshop (preregistration required)

• A live podcast with Mark Shapiro, MD, featuring discussions with hospital medicine thought leaders in an informal setting (preregistration required)

Still on the fence about attending your first SHM annual conference? First-time conference attendees can opt into 1 year of complimentary SHM membership with conference registration if they have never been a member. New members can network at an exclusive breakfast on April 16.

Find out what tools HM20 – and SHM – can offer you to take the next steps in your career in hospital medicine. Register now and see the full conference schedule at shmanualconference.org.

March 2020

8  The Hospitalist
ELEVATE YOUR HEALTHCARE CAREER

Looking for a clinical opportunity that helps reach your career goals while empowering you to deliver outstanding patient care? Visit booth 819 during the Society of Hospital Medicine Annual Conference to explore our nationwide careers.

scp-health.com/excel
**Key Clinical Question**

Which tube placement is best for a patient requiring enteral nutrition?

Comparative advantages of EN tubes

By Bibhusan Basnet, MD; Cory Gallivan, OMS III; and Carla Tayes, OMS III

**Case**

A 68-year-old diabetic nonverbal female presents to the ED because of "seizure" 1 hour ago. On exam, her blood glucose is 200. She is unable to speak and has dysphagia because of a stroke she sustained last month. The patient’s husband adds that she hasn’t been eating and drinking sufficiently in the past couple of days. Imaging was negative for any acute intracranial bleeds or lesions. Labs showed a serum sodium level of 150 milliequivalents/L. D5W is started, and the following day, the patient has a sodium level of 154 milliequivalents/L.

**Overview of the data**

Enteral nutrition should be started within 24-48 hours in a critically ill patient who is unable to maintain intake according to the American Society of Parenteral and Enteral Nutrition. This can be provided through a nasogastric (NG) tube, percutaneous endoscopic gastrostomy (PEG) tube, PEG tube with jejunal extension (PEG-J), or a percutaneous endoscopic jejunal (PEJ) tube.

NG tubes are often the first method deployed because of their low cost and convenience. They are also suitable for the patient who requires this type of feeding for less than 4 weeks. However, NG tubes do require some patient cooperation (to place and maintain) and are contraindicated in some patients with orofacial trauma, upper GI tumors, inadequate lower esophageal sphincter tone, and gastroparesis.

Another option is a PEG tube, which is a good alternative for patients who are sedated; are ventilated; or have neurodegenerative processes, stroke with dysphagia, or head and neck cancers. These are typically recommended when enteral nutrition will be needed for more than 4 weeks. Disadvantages of PEG tubes include tube obstruction or displacement, gastroesophageal reflux, and leakage of gastric content around the percutaneous site or into the peritoneum.

PEG-J tubes, PEJ tubes, or jejunostomy tubes are best suited for patients with GI dysmotility, patients who have unsuccessfully undergone the aforementioned methods, patients with histories of partial gastrectomies, or patients with gastric or pancreatic cancers/multiple traumas. The PEG-J tube extends into the distal duodenum; because it is longer and more narrow, it is more likely to coil and occlude the flow of nutrients during feedings. Jejunal feeding methods incorporate a continuous pump.
controlled infusion; if set too rapidly, this could cause dumping syndrome. A benefit of jejunal nutrition is a lower risk of aspiration, compared with other enteral tubes.4

It is best to appraise the selected method for its efficacy and patient preference. The American College of Gastroenterology recommends starting with oro-gastric or nasogastric feeds, and switching to postpyloric or jejunal feeds for those intolerant to or at high risk for aspiration.5 The most important aspect is early enteral nutrition in hospitalized patients unable to maintain oral nutrition.

Application of the data to the original case
This is a severely hypernatremic diabetic patient unable to swallow. On day 2 of her hospitalization, the clinical team provided the patient with an NG tube for increased free-water intake to gradually decrease her serum sodium. By hospital day 4, the patient’s sodium had normalized. Because of the patient’s long-term prognosis and dysphagia, discussions were held with the patient and husband for PEG tube placement. The patient received a PEG tube and was subsequently discharged 2 days later.

Bottom line
Enteral nutrition is a common need among hospitalized patients. Modality of enteral nutrition will depend on the patient’s past medical history, anticipated duration, and preferences.

References

Table 1. Evidence-Based Indications for Specialized Nutrition Support

<table>
<thead>
<tr>
<th>Indication</th>
<th>Effect on patient outcome</th>
<th>SORT evidence rating*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute severe pancreatitis</td>
<td>EN has been shown to reduce length of hospitalization and infection rates compared with PN; no effect on mortality</td>
<td>B</td>
</tr>
<tr>
<td>Bone marrow transplantation</td>
<td>PN may prevent weight loss, but is associated with increased risk of infections related to intravenous line</td>
<td>B</td>
</tr>
<tr>
<td>Burns</td>
<td>EN appears to be beneficial in improving patient outcomes, although the best time to start is not clear; early EN (within 24 hours of injury) vs. delayed EN (greater than 24 hours) may blunt the hypermetabolic response to thermal injury, but there are insufficient data to provide clear guidelines for practice</td>
<td>B</td>
</tr>
<tr>
<td>Cancer</td>
<td>EN may improve nutritional status in some patients with cancer (e.g., those who are malnourished or at risk of becoming malnourished during cancer treatment, those with a potentially curable disease, those with a long disease-free period after cancer treatment); no effect on survival; no benefit demonstrated in clinical trials of patients undergoing chemotherapy for advanced cancer; PN associated with increased rate of complications in patients undergoing chemotherapy</td>
<td>B</td>
</tr>
<tr>
<td>Critically ill</td>
<td>EN in patients who are critically ill and unable to maintain voluntary nutritional intake reduces mortality and length of stay in the ICU (most clinical trials included surgical patients in the ICU with trauma, burns, pancreatitis, and sepsis)</td>
<td>A</td>
</tr>
<tr>
<td>Crohn disease</td>
<td>Supplementary EN may be effective for maintenance of Crohn disease remission; there are insufficient data to recommend elemental vs. polymeric formulas</td>
<td>B</td>
</tr>
<tr>
<td>Cystic fibrosis</td>
<td>Observational studies suggest improved nutritional status and stabilization of lung function in patients with cystic fibrosis who are receiving EN; PN has been shown to promote weight gain, but with a higher rate of sepsis; oral nutrition support does not confer additional benefits in moderately malnourished children than the use of dietary advice and monitoring alone</td>
<td>B</td>
</tr>
<tr>
<td>Dementia</td>
<td>Patients with dementia and poor oral intake do not benefit from specialized nutrition support, percutaneous endoscopic gastrostomy tubes have been associated with poor prognosis</td>
<td>A</td>
</tr>
<tr>
<td>Gastrointestinal surgery</td>
<td>Early (within 24 hours) feeding (i.e., food intake, oral nutrition support, or EN) has been shown to reduce mortality, risk of postoperative complications, and length of hospitalization compared with no feeding</td>
<td>B</td>
</tr>
<tr>
<td>Head injury</td>
<td>Early feeding has been associated with a trend toward better survival and disability outcomes; further trials are required</td>
<td>A</td>
</tr>
<tr>
<td>Liver transplant</td>
<td>PN and EN have been associated with shorter ICU stays and improved nutritional status compared with no nutrition support</td>
<td>B</td>
</tr>
<tr>
<td>Necrotizing enterocolitis</td>
<td>There are insufficient data to inform clinical practice on the effect of delayed (at least 96 hours after birth) vs. earlier enteral feedings on necrotizing enterocolitis in infants</td>
<td>C</td>
</tr>
<tr>
<td>Older patients, malnourished</td>
<td>Oral nutrition support has been shown to produce a small but consistent weight gain in older patients who are malnourished; potential beneficial effect on complications and mortality, but confirmation is needed; no evidence of functional improvement</td>
<td>B</td>
</tr>
<tr>
<td>Short bowel syndrome</td>
<td>Five-year survival with PN is better than that with grafting after small bowel transplantation; therefore, PN is the treatment of choice in patients with short bowel syndrome when EN is not possible; potential candidates for small bowel transplantation include those with liver failure associated with PN or those with recurrent cathereter sepsis and lack of venous access</td>
<td>B</td>
</tr>
<tr>
<td>Stroke (dysphagic)</td>
<td>Early placement of an enteral feeding tube (within the first week) has not been shown to improve long-term survival, complication rates, or length of hospitalization</td>
<td>B</td>
</tr>
<tr>
<td>Very low-birth-weight infants</td>
<td>There is no evidence that early feeding affects feeding tolerance or growth rates in very low-birth-weight infants</td>
<td>B</td>
</tr>
</tbody>
</table>

EN = enteral nutrition; ICU = intensive care unit; PN = parenteral nutrition.

*B = consistent, good-quality patient-oriented evidence; R = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml. Information from references 1 through 7, and 17 through 27.

Additional Reading


A match made in medicine: Match Day 2020

By Caitlin Cowan

Match Day is the celebration of the National Resident Matching Program® (NRMP®) results, which seals the fate not only of future medical professionals, but of the program placements dedicated to supporting their careers.

Daniel Ricotta, MD, FHM, an academic hospitalist at Beth Israel Deaconess Medical Center (BIDMC) in Boston, and an active SHM member since 2013 — including his current role as a Physicians in Training Committee member — offers unique insight into the value of understanding both sides of this interview table.

As an associate program director of BIDMC's Internal Medicine Residency Program and the director of Simulation Education at the Carl J. Shapiro Center for Education & Research, Dr. Ricotta is able to act on his passions for medical education and clinical care.

"I knew I wanted to do academic medicine and education," Dr. Ricotta said. "I was able to get involved by working with students and residents early on in my career."

A natural fit for his current roles, Dr. Ricotta has gained a unique perspective on the match process and how it has evolved since he began his residency 9 years ago.

Preparing for Match Day includes an extensive checklist of life-altering to-dos that shape your career trajectory. Medical students must have noteworthy CV points, scholarly recommendations, stand-out interviews, and a thoughtful rank list — among many other things to consider through the course of the match. Dr. Ricotta said that, while this application process has generally remained the same since his participation, he has noticed that the students themselves have changed.

"Students going into residency are more mature and further along professionally," he explained. "I've seen more students go on to do something else for a while and have gained more experience."

Amidst what can feel like a free-for-all, Dr. Ricotta reminds his students that the match process is a two-sided relationship. "I certainly didn't realize how much work goes into recruitment when I was a student," Dr. Ricotta admitted. "What students don't think about is the amount of care that goes into trying to match students who share personal values, support of the mission, or are a good cultural fit."

He went on to emphasize the importance of environmental compatibility.

"Go where you feel you will thrive," he said. "Go somewhere that has a mission that resonates with your mission and think about your fellow applicants and potential mentorship. Could you see yourself being their classmate? Does this program have people there who can help you to achieve your goals?"

In part because of hospital medicine's scheduling flexibility and hands-on learning opportunities, more students are interested in exploring this specialty. "What is amazing about hospital medicine is the ample opportunity for you to get involved earlier in your career and build from that," he said. "There is more face time with patients, more training for medical students available, countless academic opportunities in research and scholarships, and even conferences."

Because of the multiple career pathways available in hospital medicine, SHM aims to provide students and residents with professional tools and opportunities as early as possible to allow them to get a preview of what they can expect as a hospitalist.

"SHM is about getting involved," said Dr. Ricotta. "SHM encourages residents to become actively incorporated into the community through chapters, conferences, and other networking opportunities on both local and national levels."

Are you a student interested in exploring a career in hospital medicine? SHM supports educational and professional needs at all stages of your career. When you join SHM during your residency training, you receive access to programs, resources, and opportunities that will enhance your skills and raise your professional profile. For more information about our Residents & Fellows membership opportunity, please visit: hospitalmedicine.org/residents.

Ms. Cowan is a marketing communications specialist at SHM.
You’re covered with a subscription to Hospital Pediatrics®

When complex cases pour in, count on the latest best practices published on pediatric inpatient care like preventing asthma readmissions and community acquired pneumonia, bronchiolitis hospitalizations, managing PICU transfers and UTIs in young febrile children, and so much more!

Hospital Pediatrics®

Management of Chorioamnionitis-Exposed Infants in the Newborn Nursery Using a Clinical Examination–Based Approach

JOSHI ET AL

Economic Burden of Home Antimicrobial Therapy: OPAT Versus Oral Therapy

KRAH ET AL

Pediatric Readmissions Within 3 Days of Discharge: Preventability, Contributing Factors, and Necessity

RODRIGUEZ ET AL

Epidemiology of Readmissions After Sepsis Hospitalization in Children

PROUT ET AL

Save 20% at checkout with promo code SOHM20

Offer expires 6/30/2020.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®
In the Literature

Clinician reviews of HM-centric research

By Nausheen Ahmed, MD; Ritu Garg, MD; Sameer Qazi, MD; Krishna Raghavan, MD; Edwin Santa, MD; Margaret Tsien, MD

Loyola University Medical Center, Maywood, Ill.

IN THIS ISSUE

1. Correlating hospitalist work schedules with patient outcomes
2. Early palliative care consultation in the medical ICU
3. Assessing the efficacy and safety of dapagliflozin in patients with HFrEF
4. Lower target LDL-C cuts risk of CV events in ischemic stroke patients
5. Efficacy and safety of daily low-dose colchicine after recent MI
6. Thyroid hormone analogues can reverse NASH
7. IV drug users: The new face of candidemia
8. Torsemide vs. furosemide in heart failure patients
9. Ruling out PE in patients with low C-PTP and D dimer of less than 1,000 ng/mL

By Nausheen Ahmed, MD

1. Correlating hospitalist work schedules with patient outcomes

CLINICAL QUESTION: How do hospitalist schedules correlate with patient care outcomes?

BACKGROUND: Studies show better outcomes, decreased length of stay, increased patient satisfaction, improved quality, and decreased readmission rates when hospitalist services are used.

This study looks at how hospitalist schedules affect these outcomes.

STUDY DESIGN: Retrospective cohort study.

SETTING: 229 hospitals in Texas.

SYNOPSIS: This cohort study used 3 years of Medicare data from 229 hospitals in Texas. It included 114,777 medical admissions of patients with a 3- to 6-day length of stay. The study used the percentage of hospitalist working days that were blocks of 7 days or longer. ICU stays and patients requiring two or more E&M codes were excluded since they are associated with greater illness severity.

The primary outcome was mortality within 30 days of discharge and secondary outcomes were 30-day readmission rates, discharge destination, and 30-day postdischarge costs.

Patients receiving care from hospitalists working several days in a row had better outcomes. It is postulated that continuity of care by one hospitalist is important for several reasons. Most importantly, the development of rapport with patient and family is key to deciding the plan of care and destination post discharge as it is quite challenging to effectively transfer all important information during verbal or written handoffs.

BOTTOM LINE: Care provided by hospitalists working more days in a row improved patient outcomes. A variety of hospitalist schedules are being practiced currently; however, these findings must be taken into account as schedules are designed.


2. Early palliative care consultation in the medical ICU

CLINICAL QUESTION: Does early palliative care consultation in critically ill patients lead to early establishment of code status and positively impact care?

BACKGROUND: Mortality rates in critically ill patients remain in excess of 20% in many institutions. In the last 2 decades, palliative care has become a core component of ICU care. Current literature recommends a palliative care consult in the ICU setting; however, implementing this recommendation in a meaningful way has been challenging. The purpose of this study is to evaluate whether consulting palliative care in ICU earlier improves patient outcomes.

STUDY DESIGN: Single-center randomized crossover trial.

SETTING: Two medical ICUs at Barnes Jewish Hospital, St. Louis.

SYNOPSIS: 199 patients were enrolled using palliative care criteria to identify patients at high risk for morbidity and mortality. In the intervention arm, patients received a palliative care consultation from an inter-professional team led by board-certified palliative care providers within 48 hours of ICU admission.

The primary outcome of this study was a change in code status to Do Not Resuscitate/Do Not Intubate (DNR/DNI), which was significantly higher in the intervention group (50.5% vs. 23.4%; P less than .0001). The intervention group also had more hospice discharges, fewer ventilated days, a lower rate of tracheostomy, and fewer hospital readmissions. However, mortality and ICU/hospital length of stay were not significantly different between the two arms. Limitations of this study include using a single academic center and the fact that establishing a DNR/DNI may not measure quality of life or patient/family satisfaction. Further studies are needed to focus on clinical outcomes as well as patient and family satisfaction.

BOTTOM LINE: Early goal-directed palliative care consults with experienced clinicians board certified in palliative care influences goals of care, code status, and discharge plans for the critically ill and can improve medical resource utilization.


Dr. Ahmed is assistant professor in the division of hospital medicine, Loyola University Medical Center, Maywood, Ill.

By Ritu Garg, MD

3 Assessing the efficacy and safety of dapagliflozin in patients with HFrEF

CLINICAL QUESTION: Can the use of dapagliflozin, in addition to guideline-directed medical therapy, improve patient-reported outcomes and health-related quality of life in patients with heart failure and reduced ejection fraction (HFrEF)?

BACKGROUND: Guideline-directed medical therapy (use of beta-blockers, ACE inhibitor/angiotensin receptor blockers, and mineralocorticoid antagonists) provides clear benefits on mortality and morbidity in patients with HFrEF. Dapagliflozin (Farxiga) belongs to a class of sodium-glucose transporter 2 (SGLT2) inhibitors that inhibits reabsorption of sodium and glucose in the kidney and treats type 2 diabetes. This new class of drugs is emerging as an effective tool in the management of HFrEF based on the recent publication of the primary results of the DAPA-HF trial (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure). It demonstrated substantial benefits in terms of heart failure symptoms, hospitalizations, and mortality when added to triple therapy for patients with chronic HFrEF regardless of the presence of diabetes.

STUDY DESIGN: Randomized, controlled double-blind trials.

SETTING: 410 participating institutions in 20 countries.

SYNOPSIS: Men and women aged 18 years and older with HFrEF who had New York Heart Association (NYHA) functional class II or higher, and optimally treated with pharmacologic and device therapy for HF were randomized to receive dapagliflozin or placebo. A total of 4,744 patients, aged 22-94 years were enrolled in the study.
Dapagliflozin showed a clinically significant benefit on health status (symptoms, physical function, and quality of life). Improved health-related quality of life (as measured by the well-validated Kansas City Cardiomyopathy Questionnaire score) with dapagliflozin in comparison with placebo was sustained for more than 8 months.

Dapagliflozin reduced the risk of death and worsening heart failure and improved symptoms across the broad spectrum of ages studied in DAPA-HF. There was no significant imbalance in tolerability or safety events between dapagliflozin and placebo, even in elderly individuals.

**BOTTOM LINE:** Follow-up DAPA-HF studies further support the role of SGLT2 inhibitor dapagliflozin in improving mortality, reducing hospitalization, and improving the quality of life in patients with HFpEF and is considered a safe option across all age groups.


### Lower target LDL-C cuts risk of CV events in ischemic stroke patients

**CLINICAL QUESTION:** Is a target LDL cholesterol (LDL-C) level of less than 70 mg/dL superior to a target LDL-C level of 90-110 mg/dL in prevention of future cardiovascular (CV) events in patients with a prior stroke of atherothrombotic origin or transient ischemic attack (TIA)?

**BACKGROUND:** The beneficial role of high-intensity statins in secondary prevention of recurrent atherosclerotic stroke is well established. It is uncertain whether the observed benefit was from a reduction in the cholesterol level or to other pleotropic effects of atorvastatin. The ideal target cholesterol level for secondary prevention is unclear. This trial was conducted to help determine an ideal target LDL-C level in the prevention of CV events following ischemic stroke.

**STUDY DESIGN:** Randomized, parallel-group, event-driven trial.

**SETTING:** Conducted in France and South Korea.

**SYNOPSIS:** In this study, patients with an ischemic stroke within the last 3 months or TIAs within 15 days were randomly assigned to receive statins with or without ezetimibe (Zetia) to achieve a higher-target LDL-C level (90-110 mg/dL) vs. lower-target LDL-C (less than 70 mg/dL). The composite primary endpoint was a major cardiovascular event, which included ischemic stroke, MI, new symptoms leading to urgent coronary or carotid revascularization, or death from CV causes.

There were 2,860 patients enrolled, 1,430 were assigned to each target group. At the end of 3.5 years, the primary endpoint occurred in 8.5% of patients in the lower target group, compared with 10.9% in the higher target group (hazard ratio, 0.78; 95% confidence interval, 0.61-0.98; P = .04). Unfortunately, the trial was stopped early because of a lack of funding.

**BOTTOM LINE:** Using medications including statins to lower the LDL-C to less than 70 mg/dL leads to better cardiovascular outcomes following ischemic stroke.
CLINICAL | In the Literature

Continued from previous page

6 Thyroid hormone analogues can reverse NASH

By Krishna Raghavan, MD

Thyroid hormone analogues can reverse NASH

BACKGROUND: Fat toxicity results in inflammation of the liver and eventual hepatic fibrosis and cirrhosis. Thyroid hormones can greatly reduce this hepatic steatosis by restoring metabolic pathways in damaged liver, prevent fibrosis progression, and have broad atherogenic lipid-lowering actions by activating hepatic thyroid beta-receptors. However, hyperthyroidism also leads to osteoporosis, tachycardia, muscle wasting, and psychiatric side effects, mediated by the alpha-thyroid receptor. Resmetirom (MGL-3196) is a novel, highly selective thyroid beta-agonist, with a minimal side-effect profile, which avoids the alpha-side effects.

STUDY DESIGN: Randomized, double-blind, placebo-controlled study.

SETTING: 25 centers in the United States.

SYNOPSIS: Of 285 adults with NASH fibrosis 1-3 and greater than 10% hepatic fat, 84 received resmetirom and 41 received placebo. Resmetirom resulted in a nearly 30% decrease over placebo in hepatic fat, compared with baseline, significant improvement in lipid profile, improvement in liver enzymes, fibrosis markers, and histologic resolution of NASH in some patients.

While the study showed resolution of inflammation, the 36-week study was likely not long enough to show improvement of fibrosis. The relatively small sample size also limited results. Placebo patients who lost significant weight also showed improvement and were excluded from analysis, suggesting that weight loss itself is also an excellent alternative to reverse NASH. Resmetirom use in NASH is now moving into a large phase 3 trial.

BOTTOM LINE: Resmetirom results in major liver and cardiovascular benefits in patients with NASH.


7 IV drug users: The new face of candidemia

By Edwin Santa, MD

FMT cuts risk of bloodstream infections in patients with recurrent CDI

BACKGROUND: Fat toxicity results in inflammation of the liver and eventual hepatic fibrosis and cirrhosis. Thyroid hormones can greatly reduce this hepatic steatosis by restoring metabolic pathways in damaged liver, prevent fibrosis progression, and have broad atherogenic lipid-lowering actions by activating hepatic thyroid beta-receptors. However, hyperthyroidism also leads to osteoporosis, tachycardia, muscle wasting, and psychiatric side effects, mediated by the alpha-thyroid receptor. Resmetirom (MGL-3196) is a novel, highly selective thyroid beta-agonist, with a minimal side-effect profile, which avoids the alpha-side effects.

STUDY DESIGN: Randomized, double-blind, placebo-controlled study.

SETTING: 25 centers in the United States.

SYNOPSIS: Of 285 adults with NASH fibrosis 1-3 and greater than 10% hepatic fat, 84 received resmetirom and 41 received placebo. Resmetirom resulted in a nearly 30% decrease over placebo in hepatic fat, compared with baseline, significant improvement in lipid profile, improvement in liver enzymes, fibrosis markers, and histologic resolution of NASH in some patients.

While the study showed resolution of inflammation, the 36-week study was likely not long enough to show improvement of fibrosis. The relatively small sample size also limited results. Placebo patients who lost significant weight also showed improvement and were excluded from analysis, suggesting that weight loss itself is also an excellent alternative to reverse NASH. Resmetirom use in NASH is now moving into a large phase 3 trial.

BOTTOM LINE: Resmetirom results in major liver and cardiovascular benefits in patients with NASH.


8 IV drug users: The new face of candidemia

By Edwin Santa, MD

FMT cuts risk of bloodstream infections in patients with recurrent CDI

BACKGROUND: Fat toxicity results in inflammation of the liver and eventual hepatic fibrosis and cirrhosis. Thyroid hormones can greatly reduce this hepatic steatosis by restoring metabolic pathways in damaged liver, prevent fibrosis progression, and have broad atherogenic lipid-lowering actions by activating hepatic thyroid beta-receptors. However, hyperthyroidism also leads to osteoporosis, tachycardia, muscle wasting, and psychiatric side effects, mediated by the alpha-thyroid receptor. Resmetirom (MGL-3196) is a novel, highly selective thyroid beta-agonist, with a minimal side-effect profile, which avoids the alpha-side effects.

STUDY DESIGN: Randomized, double-blind, placebo-controlled study.

SETTING: 25 centers in the United States.

SYNOPSIS: Of 285 adults with NASH fibrosis 1-3 and greater than 10% hepatic fat, 84 received resmetirom and 41 received placebo. Resmetirom resulted in a nearly 30% decrease over placebo in hepatic fat, compared with baseline, significant improvement in lipid profile, improvement in liver enzymes, fibrosis markers, and histologic resolution of NASH in some patients.

While the study showed resolution of inflammation, the 36-week study was likely not long enough to show improvement of fibrosis. The relatively small sample size also limited results. Placebo patients who lost significant weight also showed improvement and were excluded from analysis, suggesting that weight loss itself is also an excellent alternative to reverse NASH. Resmetirom use in NASH is now moving into a large phase 3 trial.

BOTTOM LINE: Resmetirom results in major liver and cardiovascular benefits in patients with NASH.


Continued on page 19

March 2020

The Hospitalist
Some patients who spend three or more days in an intensive or critical care unit need extended recovery time in an acute-level setting before transitioning home.

These post-intensive care patients can benefit from specialized care provided by clinicians with expertise in treating critically ill and medically complex patients.

Our interdisciplinary care features daily physician oversight, ICU/CCU-level staffing and specially trained caregivers that seek to improve outcomes and reduce costly readmissions for difficult-to-treat patients.

For a clinical assessment of your medically complex patients needing prolonged acute-level care, visit kindredhospitals.com to find our hospital nearest you.
In the Literature

Predictors of bacteremia in children hospitalized with community-acquired pneumonia

Children with blood pathogens had longer lengths of stay

By Anika Kumar, MD

CLINICAL QUESTION: Are blood cultures warranted in specific subsets of children hospitalized with community-acquired pneumonia (CAP)?

BACKGROUND: Guidelines from the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America recommend obtaining blood cultures in children hospitalized with moderate to severe community-acquired pneumonia. This group of authors recently published a study showing the prevalence of bacteremia of 2.5% in a cohort of generally healthy children hospitalized with CAP who had blood cultures obtained, with only 0.4% harboring a pathogen not susceptible to penicillin. They found low yield for blood cultures in children hospitalized with CAP.

STUDY DESIGN: Retrospective Cohort Study.

SETTING: Pediatric Health Information System Plus (PHIS+) database (six institutions).

SYNOPSIS: Secondary analysis of prior study of children aged 3 months to 18 years hospitalized with CAP between 2007 to 2011. For the secondary analysis only children in whom a blood culture was obtained on the initial or second day of hospitalization were studied. CAP was defined by a primary ICD-9 discharge diagnosis code for pneumonia or a primary ICD-9 discharge diagnosis code for pleural effusion with a secondary diagnosis code for pneumonia. Children transferred into the study institution and children with complex chronic conditions were excluded from the study. The primary outcome was the presence of bacteremia based on pathogen detection in the initial blood culture. Bacteria were labeled as pathogens or contaminants.

A total of 7,509 children were included in the initial study. Of them, 2,568 (34.2%) had a blood culture obtained on the initial or second day of hospitalization; 65 (2.5%) of the children with blood cultures obtained on admission had bacteremia. The most common penicillin-susceptible blood pathogen isolated was Streptococcus pneumoniae (n = 47). Eleven children (0.4%) had bacteremia with a pathogen not susceptible to penicillin. Children with bacteremia had a higher median admission white blood cell (WBC) count compared to children without bacteremia. Children with bacteremia had longer hospital stays compared to children without bacteremia. There were no differences in in-hospital mortality.

Dr. Kumar is a pediatric hospitalist at Cleveland Clinic Children’s. She is a clinical assistant professor of pediatrics at Case Western Reserve University, Cleveland, and serves as the Pediatrics Editor for The Hospitalist.
CLINICAL QUESTION: Can we rule out pulmonary embolism (PE) in patients with a low clinical pretest probability (C-PTP) and a D-dimer of less than 1,000 ng/mL?

BACKGROUND: A pulmonary embolism can be considered ruled out if patients have a low C-PTP for PE and a D-dimer level of less than 500 ng/mL. However, this occurs in approximately 30% of outpatients only. By increasing the D-dimer threshold used to define a negative test to 1,000 ng/mL in patients with a low C-PTP, we might be able to rule out a larger segment of patients and avoid chest imaging.

STUDY DESIGN: Prospective study.

SETTING: University-based clinical centers in Canada.

SYNOPSIS: This study enrolled 2,017 patients presenting with symptoms of PE. The Wells' criteria was used to categorize the patient's C-PTP as low (0-4.0), moderate (4.5-6.0), or high (6.5 or more). Patients with a low or moderate C-PTP had a D dimer drawn. Those with a low C-PTP and D dimer of less than 1,000 ng/mL or moderate C-PTP and a D dimer of less than 500 ng/mL underwent no further testing. Outcomes were assessed at 90 days. Of the 1,325 patients with a low C-PTP or moderate C-PTP and a negative D-dimer test (less than 1,000 or 500 ng/mL, respectively), none had venous thromboembolism during follow-up (99.5% confidence interval, 0.00-0.29). This strategy resulted in the use of chest imaging in only 34.3% of patients versus 51.9% using the prior criteria of a D-dimer level of less than 500 ng/mL (difference, −17.6 percentage points; 95% CI, −19.2 to −15.9). One limitation of the study is that almost all patients enrolled were outpatients (only one inpatient).

BOTTOM LINE: A combination of a low C-PTP and a D-dimer level of less than 1,000 ng/mL identified a group of patients at low risk for pulmonary embolism during follow-up.


Dr. Santa is assistant professor in the division of hospital medicine, Loyola University Medical Center, Maywood, Ill.

By Margaret Tsien, MD

10 Torsemide vs. furosemide in heart failure patients

CLINICAL QUESTION: Does the use of torsemide improve clinical outcomes when compared with furosemide?

BACKGROUND: Treatment goals of heart failure include improvement in quality of life, prevention of hospitalization, and decreases in mortality. Loop diuretics can improve these goals. Furosemide (Lasix) is the most widely used diuretic in heart failure patients. Torsemide (Demadex) has a better pharmacokinetic and pharmacodynamic profile than does furosemide, with greater bioavailability, a longer half-life, and higher potency. In addition, there is a suggestion that torsemide has a vasodilatory effect and a possible antialdosterone effect that may contribute to its efficacy. However, it is not known if that better profile leads to differences in outcomes in primary treatment goals.

STUDY DESIGN: Systematic review and meta-analysis.

SETTING: 19 published randomized, controlled trials (RCTs) or observational studies in the English language.

SYNOPSIS: 19 RCTs and observational studies comparing furosemide and torsemide were analyzed to identify differences in New York Heart Association functional classification, side effects, hospitalizations for heart failure, cardiac mortality, and all-cause mortality. More than 19,000 patients were included with a mean follow-up of 15 months. Torsemide was associated with a significant improvement in functional status with a number needed to treat of five. In addition, there were lower numbers of hospitalizations from heart failure and a lower risk of cardiac death in the torsemide arm though these differences disappeared when RCTs were analyzed alone. There were no differences in all-cause mortality or medication side effects between furosemide and torsemide.

BOTTOM LINE: The use of torsemide is associated with significant improvement in functional status. It is also – though less significantly – associated with lower hospitalization rates for heart failure and lower cardiac mortality.


Dr. Tsien is assistant professor in the division of hospital medicine, Loyola University Medical Center, Maywood, Ill.

NEW ANTIBIOTIC FOR COMPLICATED UTI

Fetroja (cefdicerol) is a newly approved antibacterial drug for treatments of patients aged 18 years or older with complicated urinary tract infections and otherwise limited treatment options. Safety and efficacy were demonstrated in a study of 548 patients although there was also a higher all-cause mortality rate in critically ill patients with multidrug-resistant gram-negative bacterial infections.

CITATION: FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance. FDA News Release. 2019 Nov 14

NEW ANTIBIOTIC FOR COMPLICATED UTI

Fetroja (cefdicerol) is a newly approved antibacterial drug for treatments of patients aged 18 years or older with complicated urinary tract infections and otherwise limited treatment options. Safety and efficacy were demonstrated in a study of 548 patients although there was also a higher all-cause mortality rate in critically ill patients with multidrug-resistant gram-negative bacterial infections.

CITATION: FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance. FDA News Release. 2019 Nov 14

NEW ANTIBIOTIC FOR COMPLICATED UTI

Fetroja (cefdicerol) is a newly approved antibacterial drug for treatments of patients aged 18 years or older with complicated urinary tract infections and otherwise limited treatment options. Safety and efficacy were demonstrated in a study of 548 patients although there was also a higher all-cause mortality rate in critically ill patients with multidrug-resistant gram-negative bacterial infections.

CITATION: FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance. FDA News Release. 2019 Nov 14

DRUG OF CHOICE FOR PATIENTS WITH STATUS EPILEPTICUS REFRACTORY TO BENZODIAZEPINES

In a prospective, randomized, double-blind, adaptive comparative effectiveness trial involving 384 patients with benzodiazepine-refractory convulsive status epilepticus, the anticonvulsant drugs levetiracetam, fosphenytoin, and valproate each led to seizure cessation and improved alertness by 60 minutes in approximately half the study population. The three drugs were associated with similar incident of adverse events.


INVASIVE STRATEGY VS. CONSERVATIVE TREATMENT FOR STABLE ISCHEMIC HEART DISEASE

5,179 participants with stable ischemic heart disease and evidence of moderate to severe ischemia on stress testing were randomized to optimal medical therapy versus optimal medical therapy plus routine cardiac catheterization, followed by intervention in order to evaluate the primary outcome of cardiovascular death and the secondary outcomes of stroke and all-cause mortality.

CITATION: Hochman JS. ISCHEMIA Research Group. Late-Breaking Science II: Results for the ISCHEMIA Trials: To intervene or not to intervene. AHA scientific sessions. 2019 Nov 16. Session LBS.02.
Hospitalist Opportunities with Penn State Health

Penn State Health is a multi-hospital health system serving patients and communities across central Pennsylvania. We are seeking hospitalists and nocturnists interested in joining the Penn State Health family in various settings within our system.

**What We’re Offering:**
- Academic Hospitalist and Nocturnist positions (Hershey, PA)
- Community Setting Hospitalist opportunities (Lancaster and Berks County positions)
- We’ll foster your passion for patient care and cultivate a collaborative environment rich with diversity
- Commitment to patient safety in a team approach model
- Experienced hospitalist colleagues and collaborative leadership
- Salary commensurate with qualifications
- Relocation Assistance

**What We’re Seeking:**
- Completion of an accredited training program
- Ability to acquire license in the State of Pennsylvania
- Must be able to obtain valid federal and state narcotics certificates.
- Current American Heart Association BLS and ACLS certification required.
- BE/BC in Family Medicine or Internal Medicine (position dependent)

No J1 visa waiver sponsorships available

**What the Area Offers:**
Penn State Health is located in Central Pennsylvania. Our local neighborhoods boast a reasonable cost of living whether you prefer a more suburban setting or thriving city rich in theater, arts, and culture. Our surrounding communities are rich in history and offer an abundant range of outdoor activities, arts, and diverse experiences.

We’re conveniently located within a short distance to major cities such as Philadelphia, Pittsburgh, NYC, Baltimore, and Washington DC.

For more information please contact:
Heather J. Peffley, PHR FASPR, Penn State Health Physician Recruiter
hpeffley@pennstatehealth.psu.edu

Penn State Health is committed to affirmative action, equal opportunity and the diversity of its workforce. Equal Opportunity Employer – Minorities/Women/Protected Veterans/Disabled.

---

Hospitalist Opportunities Available
The Berkshires ~ Western Massachusetts

Berkshire Health Systems is currently seeking BC/BE Internal Medicine & Med/Peds physicians to join our comprehensive Hospitalist Department
- Day, Evening and Nocturnist positions
- 7 on/7 off 10 hour shift schedule
- Previous Hospitalist experience is preferred

Located in Western Massachusetts Berkshire Medical Center is the region’s leading provider of comprehensive health care services
- 302-bed community teaching hospital
- A major teaching affiliate of the University of Massachusetts Medical School
- The latest technology including a system-wide electronic health record
- A closed ICU/CCU
- A full spectrum of Specialties to support the team.

We understand the importance of balancing work with a healthy personal lifestyle
- Located just 2½ hours from Boston and New York City
- Small town New England charm
- Excellent public and private schools
- World renowned music, art, theater, and museums
- Year round recreational activities from skiing to kayaking, this is an ideal family location.

Berkshire Health Systems offers a competitive salary and benefits package, including relocation.

Interested candidates are invited to contact:
Liz Mahan • (413) 395-7866
Emahan@bhs1.org
Apply online at: www.berkshirehealthsystems.org

---

To advertise in The Hospitalist or the Journal of Hospital Medicine

CONTACT:
Heather Gonroski
973.290.8259
hgonroski@mdedge.com

or
Linda Wilson
973.290.8243
lwilson@mdedge.com
DIVISION CHIEF, HOSPITALIST MEDICINE
DEPARTMENT OF MEDICINE
Hershey, Pennsylvania

Penn State Health Milton S. Hershey Medical Center invites applications and nominations for the position of Division Chief, Hospitalist Medicine. The successful candidate will be a nationally recognized academic leader with a substantial record of leadership, clinical and administrative accomplishments, education scholarship and/or research productivity and teaching experience. We seek candidates with prior administrative and leadership experience gained within a Department of Medicine, strong interpersonal and communication skills and demonstrated ability to effectively inspire, manage, mentor, and develop faculty and staff. Candidates must hold the degree of MD, DO, or equivalent, or MD/PhD, be board certified in internal medicine, and possess qualifications for appointment.

The Division of Hospital Medicine at Penn State Health is made up of five teaching teams, five attending teams, two nocturnists, one consult team and one triage team. Together they provide inpatient care to 140+ hospitalized patients per day. The discipline of hospital medicine grew out of the increasing complexity of patients requiring hospital care and the need for dedicated clinicians to oversee their care. There are plans to further expand the number of providers, presenting a tremendous opportunity for a visionary leader to establish a national presence.

INQUIRIES, NOMINATIONS AND EXPRESSIONS OF INTEREST, INCLUDING A CURRICULUM VITAE AND COVER LETTER, SHOULD BE SUBMITTED CONFIDENTIALLY VIA EMAIL TO Heather Peffley, PHR FASPR: hpeffley@pennstatehealth.psu.edu.

Penn State Health is committed to affirmative action, equal opportunity and the diversity of its workforce. Equal Opportunity Employer – Minorities/Women/Protected Veterans/Disabled.
Ochsner Health System is seeking physicians to join our hospitalist team. BC/BE Internal Medicine and Family Medicine physicians are welcomed to apply. Highlights of our opportunities are:

- Hospital Medicine was established at Ochsner in 1992. We have a stable 50+ member group
- 7 on 7 off block schedule with flexibility
- Dedicated nocturnists cover nights
- Base plus up to 40K in incentives
- Average census of 14-18 patients
- E-ICU intensivist support with open ICUs at the community hospitals
- EPIC medical record system with remote access capabilities
- Dedicated RN and Social Work Clinical Care Coordinators
- Community based academic appointment
- The only Louisiana Hospital recognized by US News and World Report Distinguished Hospital for Clinical Excellence award in 3 medical specialties
- Co-hosts of the annual Southern Hospital Medicine Conference
- We are a medical school in partnership with the University of Queensland providing clinical training to third and fourth year students
- Leadership support focused on professional development, quality improvement, and academic committees & projects
- Opportunities for leadership development, research, resident and medical student teaching
- Skilled nursing and long term acute care facilities seeking hospitalists and mid-levels with an interest in geriatrics
- Paid malpractice coverage and a favorable malpractice environment in Louisiana
- Generous compensation and benefits package

Ochsner Health System is Louisiana’s largest non-profit, academic, healthcare system. Driven by a mission to Serve, Heal, Lead, Educate and Innovate, coordinated clinical and hospital patient care is provided across the region by Ochsner’s 40 owned, managed and affiliated hospitals and more than 100 health centers and urgent care centers. Ochsner is the only Louisiana hospital recognized by U.S. News & World Report as a “Best Hospital” across three specialty categories caring for patients from all 50 states and more than 70 countries worldwide each year. Ochsner employs more than 25,000 employees and over 4,500 employed and affiliated physicians in over 90 medical specialties and subspecialties, and conducts more than 700 clinical research studies. For more information, please visit ochsner.org and follow us on Twitter and Facebook.

Interested physicians should click here to apply online.

Visit ochsner.org/physician Job Number 00022186

Sorry, no opportunities for J1 applications.

Ochsner is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, or disability status.

To learn more, visit www.the-hospitalist.org and click “Advertise” or contact
Heather Gonroski • 973-290-8259 • hgonroski@mdedge.com or
Linda Wilson • 973-290-8243 • lwilson@mdedge.com
Hospitalist Opportunities
Gorgeous Lakes, Ideal Climate, Award-winning Downtown

Prisma Health-Upstate employs 16,000 people, including 1,200+ physicians on staff. Our system includes clinically excellent facilities with 1,627 beds across 8 campuses. Additionally, we host 19 residency and fellowship programs and a 4-year medical education program: University of South Carolina School of Medicine–Greenville, located on Prisma Health-Upstate’s Greenville Memorial Medical Campus. Prisma Health-Upstate also has developed a unique Clinical University model in collaboration with the University of South Carolina, Clemson University, Furman University, and others to provide the academic and research infrastructure and support needed to become a leading academic health center for the 21st century.

Greenville, South Carolina is a beautiful place to live and work and is located on the I-85 corridor between Atlanta and Charlotte and is one of the fastest growing areas in the country. Ideally situated near beautiful mountain ranges, beaches and lakes, we enjoy a diverse and thriving economy, excellent quality of life and wonderful cultural and educational opportunities. Check out all that Greenville, SC has to offer! #yeahTHATgreenville

Ideal Candidates:
- BC/BE Internal Medicine Physicians
- IM procedures highly desired, but not required. Simulation center training & bedside training available if needed.
- Comfort managing critically ill patients.

Details Include:
- Group comprised of career hospitalists with low turnover
- Relocation allowance available
- EPIC Electronic Medical Record system
- 7 on/7 off schedule with 1 week of vacation per year
- Additional shifts paid at a premium

Available Opportunities:

Nocturnist, Greenville Memorial Hospital
- $340K base salary with $10K incentive bonus and CME stipend
- Up to $40K sign on bonus
- Minimum of 3 physician night coverage team
- Academic appointment and resident supervision opportunity
- Codes run by critical care team
- Full subspecialist back up

Nocturnist or Traditional Hospitalist, Baptist Easley Hospital
- $240-260K base salary with 45K incentive bonus and CME stipend for Traditional Hospitalist
- $320K base salary with $10K incentive bonus and CME stipend for Nocturnist
- Up to $40K sign on bonus for Nocturnist

Med-Peds Hospitalist or Nocturnist, Greer Memorial Hospital
- BC/BE in internal medicine-pediatrics
- $290K base salary with $45K incentive bonus and CME stipend for Med–Peds Hospitalist
- $340K base salary with $10K incentive bonus and CME stipend for Med–Peds Nocturnist
- Up to $40K sign on bonus
- Adult and pediatric specialist support in house or by phone
- Comfortable with IM procedures and managing critically ill patients

*Public Service Loan Forgiveness (PSLF) Program Qualified Employer*
Please submit a letter of interest and CV to: Natasha Durham, Physician Recruiter, Natasha.Durham@PrismaHealth.org, ph: 864-797-6114
The Medical College of Wisconsin in Milwaukee, WI has multiple openings for Assistant Professors in the Department of Medicine, Division of General Internal Medicine. Duties include teaching, patient care, clinical research, and administrative service. Will be expected to participate in all aspects of the teaching program including medical student, graduate student, GME and CME programs, and may include medical student and resident lecture series and case conferences as well as student and resident clinical supervision, and active participation in the teaching and research conferences in the Division and Department. Patient care responsibilities will be based at Froedtert Hospital as a hospitalist, nocturnist, admitter, or a combination. There will be opportunities to participate in clinical studies, formal process improvement projects and other Divisional and Department research. Will be expected to participate in administrative and/or service functions of the Department or Hospital or on Department, MCW, or Hospital committees. Requires an M.D. or foreign equivalent, successful completion of residency in internal medicine, and a license or eligibility for a license to practice medicine and surgery in the State of Wisconsin. Interested parties are invited to submit a resume to: careers@mcw.edu

As one of the nation’s largest academic hospitalist programs, we lead a variety of teaching and non-teaching inpatient and consultative services. OSUWMC Division of Hospital Medicine is dedicated to the health and well-being of our patients, team members, and our OSUWMC community. Our mission is to improve the lives of our patients and faculty by providing personalized, patient-centered, evidence-based medical care of the highest quality. Our clinical practice meets rigorous standards of scholarship, and we are devoted to serving as expert educators and mentors to the next generation of physicians.

Preferred candidates are BC/BE in Internal Medicine or Internal Medicine-Pediatrics, have work experience or residency training at an academic medical center, and possess excellent inpatient, teamwork, and clinical skills.

OSUWMC is an equal opportunity/affirmative action employer and encourages applications from women and minorities. This is not a J-1 opportunity.

INTERESTED IN LEARNING MORE?
Contact Angelyn Pierce, Recruiting Specialist, today!
P: 337.609.5115
E: Angelyn_Pierce@scp-health.com

PRACTICE MEDICINE IN A REWARDING ENVIRONMENT
We are currently searching for Hospital Medicine Physicians to complete our team in New York. We are proud to partner with Bon Secours Community Hospital - Port Jervis and Good Samaritan Hospital – Suffern to bring top-notch patient care. Clinicians will work in an autonomous practice environment with easy access to leadership within the hospital system and SCP Health.

PROGRAM BENEFITS
• Leadership and physician opportunities
• Employed status with full benefits
• Excellent compensation with CME allowance
• Onboarding support for credentialing, compliance, and legal paperwork
• Leadership development for growth within the company

GET TO KNOW THE AREA
• 200 sunny days per year
• Small town living with NYC and Newark located nearby
• Train commutes to New York City
• Family friendly communities with year-round fun

INTERESTED IN LEARNING MORE?
Contact Angelyn Pierce, Recruiting Specialist, today!
P: 337.609.2115
E: Angelyn_Pierce@scp-health.com
Facilities:

**Ballad Health Southwest Virginia**
Johnston Memorial Hospital, Russell County Medical Center, Smyth County Community Hospital, Norton Community Hospital, Mountain View Regional Medical Center, Lonesome Pine Hospital

**Ballad Health Northeast Tennessee**
Johnson City Medical Center, Holston Valley Medical Center, Bristol Regional Medical Center and Hawkins County Memorial Hospital

Please Contact:
Tina McLaughlin, CMSR
Ballad Health Senior Physician Recruiter
O) 276-258-4580
tina.mclaughlin@balladhealth.org

---

**Employment Opportunity in the Beautiful Adirondack Mountains of Northern New York**

Current Opening for a full-time, Hospital Employed Hospitalist. This opportunity provides a comfortable 7 on/7 off schedule, allowing ample time to enjoy all that the Adirondacks have to offer!

Come live where others vacation!

- Convenient schedules
- Competitive salary & benefits
- Unparalleled quality of life
- Family friendly community
- Excellent schools
- Nearby Whiteface Mountain ski resort
- Home of the 1932 & 1980 Winter Olympics and current Olympic Training Center
- Annual Ironman Competition
- World Cup Bobsled and Ski Events
- Abundant arts community
- Hike, fish, ski, golf, boat or simply relax and take in the beauty and serenity of the Adirondack Mountains

Contact: Joanne Johnson
518-897-2706
jjohnson@adirondackhealth.org
www.adirondackhealth.org
**Survey Insights**

**Hospital medicine physician leaders**

The right skills and time to develop them

By Mihir Patel, MD

When you get someone who knows what quality looks like and pair that with curiosity about new ways to think about leading, you end up with the people who are able to produce dramatic innovations in the field. In medicine, a physician is trained to take charge in emergent situations and make potentially lifesaving efforts. However, when it comes to leading teams of individuals, not only must successful leaders have the right skills, they also need time to dedicate to the work of leadership.

To better understand current approaches to dedicated hospital medicine group (HMG) leadership time, let’s examine the 2018 State of Hospital Medicine (SoHM) Report. The survey, upon which the Report was based, examined two aspects of leadership: 1) how much dedicated time a leader receives to manage the group; and 2) how the leader’s time is compensated. Looking closely at the data displayed in graphs from the SoHM Report (Figures 1, 2, and 3), we can see that dedicated administrative time is directly proportional to the size of the group.

In my current role as a regional medical director in the Dallas–Fort Worth market, I oversee some programs where the size is greater than 30 full-time equivalents (FTEs), and requires a full-time administrative physician leader to manage the group. Their daily administrative duties include, but are not limited to, addressing physician performance and behaviors, managing team performance metrics, dealing with consultants’ expectations, attending and leading various committee meetings at the hospital or the system level, attending and presenting performance reviews, and leading and preparing for team meetings, as well as addressing and being innovative in leading new initiatives from the hospital partner system.

Although physician leaders are paid more for their work, the 2018 SoHM Report reveals a decline in the premium year over year. One of the reasons for the payment decline that I have encountered in various groups is that their incentives for leading the group are based on performance, as opposed to receiving a fixed stipend. Another reason is the presence of dedicated administrative support or the inclusion of a performance improvement staff, such as an additional nurse or advanced practice provider, in the group.

Evidence suggests that organizations and patients benefit when physicians take on leadership roles. Physician leaders play critical roles in providing high-quality patient care. How can the Society of Hospital Medicine help? Management degrees and leadership workshops have become a common pathway for many physicians, including myself. SHM provides one of the most thorough and relevant experiences through the SHM Leadership Academy. The focus of the Leadership Academy is on developing a broad set of additional leadership competencies across a spectrum of experience. As hospitalist physicians are often expected to fulfill a broader leadership void, we must pay attention to developing the leadership skills depicted in Figure 3. Hospital medicine is an ideal “proving ground” for future physician leaders.

**Figure 1:** Portion of FTE dedicated for Administrative duties of Lead Physician, by group size.

**Figure 2:** Compensation Premium for Lead Physician compared to hospitalists by year.

**Figure 3:** Changing Professional Skill Requirements

---

Dr. Patel is a regional medical director with Sound Physicians. He manages more than 100 FTE hospitalists and advanced-practice providers (APPs) within multiple health systems and hospitals in the Texas market. He also serves as a member of the SHM Practice Analysis Committee and as a vice president of SHM North Texas Chapter.

Continued on following page
Medicare study evaluates impact of U.S. hospital readmissions program

By Doug Brunk
MDedge News

Among Medicare beneficiaries admitted to the hospital between 2008 and 2016, there was an increase in postdischarge 30-day mortality for patients with heart failure, but not for those with acute myocardial infarction or pneumonia.

The finding comes from an effort to evaluate the use of services soon after discharge for conditions targeted in the U.S. Hospital Readmissions Reduction Program (HRRP), and patients’ outcomes.

“The announcement and implementation of the HRRP were associated with a reduction in readmissions within 30 days of discharge for heart failure, acute myocardial infarction, and pneumonia, as shown by a decrease in the overall national rate of readmissions,” wrote Rohan Khera, MD, and colleagues in a study published in the British Medical Journal (doi:10.1136/bmj.l6831).

“Concerns existed that pressures to reduce readmissions had led to the evolution of care patterns that may have adverse consequences through reducing access to care in appropriate settings. Therefore, determining whether patients who are seen in acute care settings, but not admitted to hospital, experience an increased risk of mortality is essential.”

The study strongly suggests that the HRRP “did not lead to harm through inappropriate triage of patients at high risk to observation units and the emergency department, and therefore provides evidence against calls to curtail the program owing to this theoretical concern (see JAMA 2018;320:2539-41),” the researchers concluded.

Continued from previous page

executives and leaders, as they often share the same characteristics required for success.

The leadership paths available in my organization, Sound Physicians, were recently highlighted in a New York Times article.5 Sound Physicians employs more than 3,000 physicians across the country, and has a pipeline for doctors to advance through structured rungs of leadership – emphasizing a different mix of clinical, strategic, and business skills at each stage, from individual practitioner to the C-suite. The training includes in-person and online courses, as well as an annual conference, to help doctors develop management and leadership competencies, and learn how to apply these skills within their organizations. Since introducing its leadership development program, the company reports less turnover, higher morale, and better growth. I personally have gone through the leadership training provided by Sound Physicians, and reflecting back, it has been a transformational experience for me. Leadership is a journey, not a destination, and as physicians we should strive to learn more from the health care leaders around us.

The administrative workload for hospital-based physician leaders will increase with the arrival of value-based programs and alternative payment models promoted by the Centers for Medicare & Medicaid Services. Lead hospitalist duties are not limited to daily operations, but can extend to leading the strategic vision of the hospital or health system. The 2020 SoHM Report will reflect these changes, as well as provide further information about how to manage and set expectations for physician leaders, based on group size and employment model.

References
This advertisement is not available for the digital edition.